Inclusion Criteria:
  1. Male or female subject 18 years of age or older
  2. Subjects with moderate to severe DLE with at least one active discoid target lesion (0.5-1.0 cm2), with CLASI â‰¥ 5.
  3. Willingness of subject to follow all study procedures
  4. Willingness to avoid excessive exposure of diseased areas to natural or artificial sunlight
Exclusion Criteria:
  1. Pregnancy or breast feeding
  2. Any condition or therapy that in the investigator's opinion may pose a risk to the subject or that could interfere with any evaluation in the study
  3. Systemic Lupus Erythematosus (SLE) as defined by ACR criteria
  4. Known hypersensitivity to any of the constituents or excipients of the investigational product
  5. Use of any prescription or non-prescription medication that could interfere with efficacy evaluations in the study
  6. Change in use of systemic DLE therapy, e.g. systemic corticosteroids, cyclosporine A, azathioprine, mycophenolate mofetil, in the past 1 month.
  7. Use of systemic pain medications, e.g. oxycodone in the past 2 weeks
  8. Participation in another clinical research study with an investigational drug within 4 weeks before this study
  9. Use of immune-suppressant or other biological treatment
 10. Starting antimalarial medicine after enrolling in the study. Subjects who are already on a stable dose of antimalarial before enrollment, may continue the same dose.
 11. An ongoing infection.